Similarly, the tumor weight on day 22 exhibited the same trend in these groups (Fig. 1E), suggesting that the combined therapy increased antitumor efficacy compared with that in the PD-1 inhibitor monotherapy against LLC in mice. This evidence concerns the gene PDCD1 and neoplasm.